This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kailasam, M. T. Articles by O'Connor, D. T. Search for Related Content PubMed PubMed Citation Articles by Kailasam, M. T. Articles by O'Connor, D. T.

(Hypertension. 1995;26:143-149.)
© 1995 American Heart Association, Inc.

Articles

Divergent Effects of Dihydropyridine and Phenylalkylamine Calcium Channel Antagonist Classes on Autonomic Function in Human Hypertension

Mala T. Kailasam; Robert J. Parmer; Justine H. Cervenka; Regina A. Wu; Michael G. Ziegler; Brian P. Kennedy; Isaac A. Adegbile; Daniel T. O'Connor

From the Department of Medicine, University of California, and Department of Veterans Affairs Medical Center, San Diego, Calif.

Abstract Calcium channel antagonists differ by class in reported frequency of side effects that suggest reflex sympathoadrenal activation. Do such differences result from differential effects on autonomic and baroreflex function? The present study compared acute and chronic effects of two classes of calcium channel antagonists, the dihydropyridine type (felodipine) and the phenylalkylamine type (verapamil), on efferent sympathetic outflow and baroreflex slope in 15 essential hypertensive subjects. Blood pressure, heart rate, hemodynamics, and biochemistries were determined at baseline and after acute (first dose) and chronic (4 weeks) administration of the drugs versus placebo. Acutely, felodipine caused a greater decrease in blood pressure associated with a larger decline in systemic vascular resistance than the corresponding effects produced by verapamil. Chronically, there were similar, significant declines in blood pressure (P=.001) and systemic vascular resistance (P=.001) after each drug. Acutely, increased sympathetic activity after felodipine was suggested by reflex tachycardia (from 69±3 to 74±2 beats per minute, P=.014) and elevation of plasma norepinephrine (from 264±25 to 323±25 pg/mL, P=.037), whereas after verapamil the corresponding changes were closely similar to those after placebo. Chronically, verapamil suppressed sympathetic activity, as evidenced by a decrease in resting heart rate (from 76±2 to 69±3 beats per minute, P=.002), decrease in plasma norepinephrine (from 264±25 to 178±21 pg/mL, P<.001), decrease in chromogranin A (from 33.0±2.4 to 27.8±1.7 ng/mL, P<.001), and lessened response of mean arterial pressure (P=.006) and heart rate (P=.016) to phentolamine -adrenergic blockade; after chronic felodipine, all of these variables were unchanged. Neither drug affected baroreflex slope. We conclude that felodipine and verapamil have qualitatively different, time-dependent actions on efferent sympathetic nervous system activity, actions that may in part explain the disparity in autonomic/hemodynamic side effect profiles of the dihydropyridine and phenylalkylamine classes of calcium channel antagonists.

Key Words: catecholamines • hypertension, essential • baroreflex • verapamil • felodipine • autonomic nervous system • sympathetic nervous system • chromogranins

This article has been cited by other articles:

				R. E. Maser and M. J. Lenhard Cardiovascular Autonomic Neuropathy Due to Diabetes Mellitus: Clinical Manifestations, Consequences, and Treatment J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5896 - 5903. [Abstract] [Full Text] [PDF]

				C. Binggeli, R. Corti, I. Sudano, T. F. Luscher, and G. Noll Effects of Chronic Calcium Channel Blockade on Sympathetic Nerve Activity in Hypertension Hypertension, April 1, 2002; 39(4): 892 - 896. [Abstract] [Full Text] [PDF]

				R. Büscher, V. Herrmann, K. M. Ring, M. T. Kailasam, D. T. O'Connor, R. J. Parmer, and P. A. Insel Variability in Phenylephrine Response and Essential Hypertension: A Search for Human alpha 1B-Adrenergic Receptor Polymorphisms J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 793 - 798. [Abstract] [Full Text]

				G. Ligtenberg, P. J. Blankestijn, P. L. Oey, I. H.H. Klein, L.-T. Dijkhorst-Oei, F. Boomsma, G. H. Wieneke, A. C. van Huffelen, and H. A. Koomans Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure N. Engl. J. Med., April 29, 1999; 340(17): 1321 - 1328. [Abstract] [Full Text] [PDF]

				P. Palatini, E. Casiglia, S. Julius, and A. C. Pessina High Heart Rate: A Risk Factor for Cardiovascular Death in Elderly Men Arch Intern Med, March 22, 1999; 159(6): 585 - 592. [Abstract] [Full Text] [PDF]

				M. L. Iabichella, G. Dell'Omo, E. Melillo, and R. Pedrinelli Calcium Channel Blockers Blunt Postural Cutaneous Vasoconstriction in Hypertensive Patients Hypertension, March 1, 1997; 29(3): 751 - 756. [Abstract] [Full Text]

				M. Epstein and G. Bakris Newer Approaches to Antihypertensive Therapy: Use of Fixed-Dose Combination Therapy Arch Intern Med, September 23, 1996; 156(17): 1969 - 1978. [Abstract] [PDF]

				M. Mahata, S. K. Mahata, R. J. Parmer, and D. T. O'Connor Vesicular Monoamine Transport Inhibitors: Novel Action at Calcium Channels to Prevent Catecholamine Secretion Hypertension, September 1, 1996; 28(3): 414 - 420. [Abstract] [Full Text]